ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40517166

Advances in molecular pathology and therapy of non-small cell lung cancer.

Huang Q and 9 others. Signal Transduct Target Ther, 2025. Cited by 148 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Advances in molecular pathology and therapy of non-small cell lung cancer. Papers, record 40517166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40517166

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advances in molecular pathology and therapy of non-small cell lung cancer.
PubMed
Journal
Signal Transduct Target Ther
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
148
iCite
Relative citation ratio, by iCite
37.62, provisional
iCite
Revised in PubMed
2026-08-05
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Huang QQing
2Li YYuanxiang
3Huang YYingdan
4Wu JJingyi
5Bao WWendai
6Xue CChang
7Li XXiaoyu
8Dong SShuang
9Dong ZZhiqianghttps://orcid.org/0000-0001-6259-915X
10Hu SSheng

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Humans
Immunotherapy
Molecular Targeted Therapy
Drug Resistance, Neoplasm

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References858

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136,122,315Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.J Clin Oncol2023https://conductscience.org/library/papers/36122315PubMed
237,459,578Immune Resistance Mechanisms and the Road to Personalized Immunotherapy.Am Soc Clin Oncol Educ Book2023https://conductscience.org/library/papers/37459578PubMed
334,986,285Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med2022https://conductscience.org/library/papers/34986285PubMed
436,380,066Barriers in access to oncology drugs - a global crisis.Nat Rev Clin Oncol2023https://conductscience.org/library/papers/36380066PubMed
519,692,680Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009https://conductscience.org/library/papers/19692680PubMed
637,657,479Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?Lancet Oncol2023https://conductscience.org/library/papers/37657479PubMed
77,046,483Historical notes on lung cancer before and after Graham's successful pneumonectomy in 1933.Am J Surg1982https://conductscience.org/library/papers/7046483PubMed
837,327,461
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
J Clin Oncol2023https://conductscience.org/library/papers/37327461PubMed
938,252,907
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
J Clin Oncol2024https://conductscience.org/library/papers/38252907PubMed
1029,023,213
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
J Clin Oncol2017https://conductscience.org/library/papers/29023213PubMed

1 to 10 of 858

See all 858 references

Cited by135

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 148 citations.

PMIDTitleJournalYearIn PapersSource
42,983,362Integrated analysis identifies an aging-related prognostic signature for lung adenocarcinoma.BMC Cancer2026https://conductscience.org/library/papers/42983362PubMed
42,967,964Integration of genome-wide association study and single-cell transcriptome analysis reveals the role of N6-methyladenosine in treatment resistance in lung cancer.Cell Biol Toxicol2026https://conductscience.org/library/papers/42967964PubMed
42,958,602Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation.Exp Hematol Oncol2026https://conductscience.org/library/papers/42958602PubMed
42,958,526Synergistic fluvastatin-nanotherapy suppresses DEPDC1-associated glycolysis and exosomal CCL2 to modulate the immune microenvironment in lung adenocarcinoma.J Nanobiotechnology2026https://conductscience.org/library/papers/42958526PubMed
42,955,441SLC2A1 promotes chemo-immunotherapy resistance in lung adenocarcinoma by modulating the AKT signaling pathway.Funct Integr Genomics2026https://conductscience.org/library/papers/42955441PubMed
42,941,865Circulating Tumour Cell GALNT13 Expression Is Associated with Prognosis and Treatment Response in Non-Small Cell Lung Cancer.Int J Mol Sci2026https://conductscience.org/library/papers/42941865PubMed
42,940,039Current Evidence on Gene-Based and Epigenetic Therapeutic, Diagnostic, and Prognostic Strategies in Epithelial-Derived Carcinomas: A Scoping Review.Biomedicines2026https://conductscience.org/library/papers/42940039PubMed
42,911,237Lung cancer metabolism: a dynamic and adaptive network.Cell Mol Life Sci2026https://conductscience.org/library/papers/42911237PubMed
42,889,733Case Report: Synchronous double primary male breast cancer and non-small cell lung cancer: diagnostic confirmation and multidisciplinary management.Front Med (Lausanne)2026https://conductscience.org/library/papers/42889733PubMed
42,889,653Exploring the immune enhancement effect of radiotherapy combined with NK cells on non-small cell lung cancer based on proteomics technology.Oncol Rev2026https://conductscience.org/library/papers/42889653PubMed

1 to 10 of 135

See all 135 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40517166

GET https://conductscience.org/api/papers/v1/40517166/references?page=2

API referenceFor AI assistants